Systemic sclerosis interstitial lung disease — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Interstitial lung disease progression
Anti-topoisomerase I and diffuse cutaneous systemic sclerosis are strongly associated with interstitial lung disease, and HRCT already shows early change. Pulmonary function testing and serial assessment are needed to monitor progression. PAH also requires screening in systemic sclerosis, but the data here point most directly to ILD.
Reference: BSR systemic sclerosis guideline 2024; EULAR systemic sclerosis recommendations